newsfilter
← Latest News
Business Wire·

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the